128 related articles for article (PubMed ID: 38781268)
1. Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
Broshkevitch CJ; Barnabas RV; Liu G; Palanee-Phillips T; Rao DW
PLoS One; 2024; 19(5):e0301997. PubMed ID: 38781268
[TBL] [Abstract][Full Text] [Related]
2. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
[TBL] [Abstract][Full Text] [Related]
3. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
van Schalkwyk C; Moodley J; Welte A; Johnson LF
Int J Cancer; 2021 Oct; 149(8):1564-1575. PubMed ID: 34164807
[TBL] [Abstract][Full Text] [Related]
5. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
6. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
Poljak M; Šterbenc A; Lunar MM
Expert Rev Anti Infect Ther; 2017 Nov; 15(11):987-999. PubMed ID: 29027811
[TBL] [Abstract][Full Text] [Related]
7. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa.
Taku O; Mbulawa ZZA; Phohlo K; Garcia-Jardon M; Businge CB; Williamson AL
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670231
[TBL] [Abstract][Full Text] [Related]
9. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis.
Kelly H; Weiss HA; Benavente Y; de Sanjose S; Mayaud P;
Lancet HIV; 2018 Jan; 5(1):e45-e58. PubMed ID: 29107561
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa.
Rohner E; Sengayi M; Goeieman B; Michelow P; Firnhaber C; Maskew M; Bohlius J
Int J Cancer; 2017 Aug; 141(3):488-496. PubMed ID: 28440019
[TBL] [Abstract][Full Text] [Related]
11. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control.
Ndizeye Z; Vanden Broeck D; Lebelo RL; Bogers J; Benoy I; Van Geertruyden JP
PLoS One; 2019; 14(6):e0209303. PubMed ID: 31237894
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana.
Tawe L; MacDuffie E; Narasimhamurthy M; Wang Q; Gaseitsiwe S; Moyo S; Kasvosve I; Shin SS; Zetola NM; Paganotti GM; Grover S
Int J Cancer; 2020 Mar; 146(6):1667-1673. PubMed ID: 31325316
[TBL] [Abstract][Full Text] [Related]
14. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
15. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.
Man I; Georges D; de Carvalho TM; Ray Saraswati L; Bhandari P; Kataria I; Siddiqui M; Muwonge R; Lucas E; Berkhof J; Sankaranarayanan R; Bogaards JA; Basu P; Baussano I
Lancet Oncol; 2022 Nov; 23(11):1419-1429. PubMed ID: 36174583
[TBL] [Abstract][Full Text] [Related]
18. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
19. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
